References
- Young NS, Issaragrasil S, Chieh CW, Takaku F. Aplastic anaemia in the Orient. Br J Haematol. 1986;62:1–6.
- Baumann I, Niemeyer CM, Bennett JM, Shannon KChildhood myelodysplastic syndrome. In:, Swerdlow S H, et al.., editors. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008. p. 104–7.
- Camitta BM, Thomas ED, Nathan DG, Gale PR, Kopecky KJ, Rappeport JM, et al.. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood. 1979;53:504.
- Bennett JM, Orazi A. Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach. Haematologica. 2009;94:264–8.
- Rajnoldi AC, Fenu S, Kerndrup G, van Wering ER, Niemeyer CM, Baumann I, et al.. Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS). Ann Hematol. 2005;84:429–33.
- Davies JK, Guinan EC. An update on the management of severe idiopathic aplastic anaemia in children. Br J Haematol. 2007;136:549–64.
- Locasciulli A, Oneto R, Bacigalupo A, Socié G, Korthof E, Bekassy A, et al.. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007;92:11–8.
- Meyers G, Maziarz RT. Is it time for a change? The case for early application of unrelated allo-SCT for severe aplastic anemia. Bone Marrow Transplant. 2010;45:1479–88.
- Kojima S, Hibi S, Kosaka Y, Yamamoto M, Tsuchida M, Mugishima H, et al.. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;69:2049–54.
- Kosaka Y, Yagasaki H, Sano K, Kobayashi R, Ayukawa H, Kaneko T, et al.. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood. 2008;111:1054–9.
- Yagasaki H, Kojim S, Yabe H, Kato K, Kigasawa H, Sakamaki H, et al.. Acceptable HLA-mismatching in unrelated donor bone marrow transplantation for patients with acquired severe aplastic anemia. Blood. 2011;118:3186–90.
- Passweg JR, Pérez WS, Eapen M, Camitta BM, Gluckman E, Hinterberger W, et al.. Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. Bone Marrow Transplant. 2006;37:641–9.
- Morishima Y, Sasazuki T, Inoko H, Juji T, Akaza T, Yamamoto K, et al.. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002;99:4200–6.
- Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, et al.. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110:4576–83.
- Maury S, Balère-Appert ML, Chir Z, Boiron JM, Galambrun C, Yakouben K, et al.. Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient. Haematologica. 2007;92:589–96.
- Kojima S, Matsuyama T, Kato S, Kigasawa H, Kobayashi R, Kikuta A, et al.. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood. 2002;100:799–803.
- Deeg HJ, Seidel K, Casper J, Anasetti C, Davies S, Gajeweski JL, et al.. Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. Biol Blood Marrow Transplant. 1999;5:243–52.